Excessive thyroid hormone replacement therapy

James Nuovo, A. Ellsworth, D. B. Christensen, R. Reynolds

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Excessive thyroid hormone replacement carries the potential for serious long-term metabolic complications (e.g., accelerated osteoporosis). The increased bioavailability of commercially available products, along with improved laboratory assays for measuring thyrotropin (TSH), has led to an increased change of actual or detected iatrogenic hyperthyroxinemia. The purpose of this study was to determine the frequency of excessive prescribing and to examine the impact of changes in potency of replacement thyroid hormone formulations and sensitivity of thyroid function tests on its incidence. Methods: A retrospective chart review was done of patients requiring thyroid hormone replacement therapy treated at a university-based, family medicine residency training program. The following information was extracted from each chart: specific thyroid medication (including dose and date of onset of therapy) and thyroid laboratory tests results (including serum thyroxine [T4] and TSH). This information from two different time periods (1975 to 1981 and 1982 to 1989) was compared using one-way analysis of variance. Results: Serum T4 levels were not significantly different between the two time periods, 1975 to 1981 and 1982 to 1989 (8.06 ± 2.93 μg/dL versus 9.0 ± 03.69 μg/dL; NS), despite significant changes in TS serum levels (23.6 ± 38.9 mIU/mL versus 7.44 ± 18.7 mIU/mL; P = 0.009) and levothyroxine dosage (184 ± 59.6 μg/d versus 145 ± 64.1 μg/d; P = 0.002). Significantly more patients had low (supersuppressed) TSH levels between 1982 and 1990 than between 1975 and 1981 (33 percent versus 10 percent; P = 0.02). Conclusions: Excessive thyroid hormone replacement with iatrogenic hyperthyroxinemia is a common occurrence. Clinicians need to be aware of this problem and implement measures (e.g., periodic monitoring of TSH) to minimize the occurrence of overdosing and the potential for long-term complications.

Original languageEnglish (US)
Pages (from-to)435-439
Number of pages5
JournalJournal of the American Board of Family Practice
Volume8
Issue number6
StatePublished - 1995
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Thyroid Hormones
Hyperthyroxinemia
Thyroxine
Thyroid Gland
Serum
Thyroid Function Tests
Thyrotropin
Internship and Residency
Biological Availability
Osteoporosis
Analysis of Variance
Medicine
Education
Incidence
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Nuovo, J., Ellsworth, A., Christensen, D. B., & Reynolds, R. (1995). Excessive thyroid hormone replacement therapy. Journal of the American Board of Family Practice, 8(6), 435-439.

Excessive thyroid hormone replacement therapy. / Nuovo, James; Ellsworth, A.; Christensen, D. B.; Reynolds, R.

In: Journal of the American Board of Family Practice, Vol. 8, No. 6, 1995, p. 435-439.

Research output: Contribution to journalArticle

Nuovo, J, Ellsworth, A, Christensen, DB & Reynolds, R 1995, 'Excessive thyroid hormone replacement therapy', Journal of the American Board of Family Practice, vol. 8, no. 6, pp. 435-439.
Nuovo, James ; Ellsworth, A. ; Christensen, D. B. ; Reynolds, R. / Excessive thyroid hormone replacement therapy. In: Journal of the American Board of Family Practice. 1995 ; Vol. 8, No. 6. pp. 435-439.
@article{fdb706485ca040e4868d26a6fe9c102c,
title = "Excessive thyroid hormone replacement therapy",
abstract = "Background: Excessive thyroid hormone replacement carries the potential for serious long-term metabolic complications (e.g., accelerated osteoporosis). The increased bioavailability of commercially available products, along with improved laboratory assays for measuring thyrotropin (TSH), has led to an increased change of actual or detected iatrogenic hyperthyroxinemia. The purpose of this study was to determine the frequency of excessive prescribing and to examine the impact of changes in potency of replacement thyroid hormone formulations and sensitivity of thyroid function tests on its incidence. Methods: A retrospective chart review was done of patients requiring thyroid hormone replacement therapy treated at a university-based, family medicine residency training program. The following information was extracted from each chart: specific thyroid medication (including dose and date of onset of therapy) and thyroid laboratory tests results (including serum thyroxine [T4] and TSH). This information from two different time periods (1975 to 1981 and 1982 to 1989) was compared using one-way analysis of variance. Results: Serum T4 levels were not significantly different between the two time periods, 1975 to 1981 and 1982 to 1989 (8.06 ± 2.93 μg/dL versus 9.0 ± 03.69 μg/dL; NS), despite significant changes in TS serum levels (23.6 ± 38.9 mIU/mL versus 7.44 ± 18.7 mIU/mL; P = 0.009) and levothyroxine dosage (184 ± 59.6 μg/d versus 145 ± 64.1 μg/d; P = 0.002). Significantly more patients had low (supersuppressed) TSH levels between 1982 and 1990 than between 1975 and 1981 (33 percent versus 10 percent; P = 0.02). Conclusions: Excessive thyroid hormone replacement with iatrogenic hyperthyroxinemia is a common occurrence. Clinicians need to be aware of this problem and implement measures (e.g., periodic monitoring of TSH) to minimize the occurrence of overdosing and the potential for long-term complications.",
author = "James Nuovo and A. Ellsworth and Christensen, {D. B.} and R. Reynolds",
year = "1995",
language = "English (US)",
volume = "8",
pages = "435--439",
journal = "Journal of the American Board of Family Medicine",
issn = "1557-2625",
publisher = "American Board of Family Medicine",
number = "6",

}

TY - JOUR

T1 - Excessive thyroid hormone replacement therapy

AU - Nuovo, James

AU - Ellsworth, A.

AU - Christensen, D. B.

AU - Reynolds, R.

PY - 1995

Y1 - 1995

N2 - Background: Excessive thyroid hormone replacement carries the potential for serious long-term metabolic complications (e.g., accelerated osteoporosis). The increased bioavailability of commercially available products, along with improved laboratory assays for measuring thyrotropin (TSH), has led to an increased change of actual or detected iatrogenic hyperthyroxinemia. The purpose of this study was to determine the frequency of excessive prescribing and to examine the impact of changes in potency of replacement thyroid hormone formulations and sensitivity of thyroid function tests on its incidence. Methods: A retrospective chart review was done of patients requiring thyroid hormone replacement therapy treated at a university-based, family medicine residency training program. The following information was extracted from each chart: specific thyroid medication (including dose and date of onset of therapy) and thyroid laboratory tests results (including serum thyroxine [T4] and TSH). This information from two different time periods (1975 to 1981 and 1982 to 1989) was compared using one-way analysis of variance. Results: Serum T4 levels were not significantly different between the two time periods, 1975 to 1981 and 1982 to 1989 (8.06 ± 2.93 μg/dL versus 9.0 ± 03.69 μg/dL; NS), despite significant changes in TS serum levels (23.6 ± 38.9 mIU/mL versus 7.44 ± 18.7 mIU/mL; P = 0.009) and levothyroxine dosage (184 ± 59.6 μg/d versus 145 ± 64.1 μg/d; P = 0.002). Significantly more patients had low (supersuppressed) TSH levels between 1982 and 1990 than between 1975 and 1981 (33 percent versus 10 percent; P = 0.02). Conclusions: Excessive thyroid hormone replacement with iatrogenic hyperthyroxinemia is a common occurrence. Clinicians need to be aware of this problem and implement measures (e.g., periodic monitoring of TSH) to minimize the occurrence of overdosing and the potential for long-term complications.

AB - Background: Excessive thyroid hormone replacement carries the potential for serious long-term metabolic complications (e.g., accelerated osteoporosis). The increased bioavailability of commercially available products, along with improved laboratory assays for measuring thyrotropin (TSH), has led to an increased change of actual or detected iatrogenic hyperthyroxinemia. The purpose of this study was to determine the frequency of excessive prescribing and to examine the impact of changes in potency of replacement thyroid hormone formulations and sensitivity of thyroid function tests on its incidence. Methods: A retrospective chart review was done of patients requiring thyroid hormone replacement therapy treated at a university-based, family medicine residency training program. The following information was extracted from each chart: specific thyroid medication (including dose and date of onset of therapy) and thyroid laboratory tests results (including serum thyroxine [T4] and TSH). This information from two different time periods (1975 to 1981 and 1982 to 1989) was compared using one-way analysis of variance. Results: Serum T4 levels were not significantly different between the two time periods, 1975 to 1981 and 1982 to 1989 (8.06 ± 2.93 μg/dL versus 9.0 ± 03.69 μg/dL; NS), despite significant changes in TS serum levels (23.6 ± 38.9 mIU/mL versus 7.44 ± 18.7 mIU/mL; P = 0.009) and levothyroxine dosage (184 ± 59.6 μg/d versus 145 ± 64.1 μg/d; P = 0.002). Significantly more patients had low (supersuppressed) TSH levels between 1982 and 1990 than between 1975 and 1981 (33 percent versus 10 percent; P = 0.02). Conclusions: Excessive thyroid hormone replacement with iatrogenic hyperthyroxinemia is a common occurrence. Clinicians need to be aware of this problem and implement measures (e.g., periodic monitoring of TSH) to minimize the occurrence of overdosing and the potential for long-term complications.

UR - http://www.scopus.com/inward/record.url?scp=0028793742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028793742&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 435

EP - 439

JO - Journal of the American Board of Family Medicine

JF - Journal of the American Board of Family Medicine

SN - 1557-2625

IS - 6

ER -